Abbvie Accuses Takeda of Failing to Meet Lupron Supply Agreement

Nov. 9, 2020, 5:30 PM

A unit of Abbvie Inc. accused Japanese drugmaker Takeda Pharmaceutical Co.of failing to produce enough of the cancer drug Lupron to fulfill a supply agreement.

Officials of AbbVie Endocrine Inc. contend in a lawsuit filed in Delaware Chancery Court that Takeda either didn’t produce enough syringe-filled units of Lupron or is improperly allocating them to other customers.

In June, U.S. regulators warned Takeda about manufacturing problems uncovered at its plant in Hikari, Japan, that produces Lupron and the Crohn’s disease drug Entyvio for the U.S. market. Fixing those problems triggered a Lupron shortage, the company said in earnings reports. ...

To read the full article log in. To learn more about a subscription click here.